Difference between revisions of "C4 glomerulopathy historical perspective"

Jump to: navigation, search
(Created page with "__NOTOC__ {{C4 glomerulopathy}} {{CMG}}; {{APM}}; {{AE}} {{OO}} ==Overview== ==Historical Perspective== ==References== {{Reflist|2}} {{WH}}{{WS}}")
 
(Historical Perspective)
Line 6: Line 6:
  
 
==Historical Perspective==
 
==Historical Perspective==
 +
C4 Nephritic factor (NeF) was first defined in 1980 by Halbwachs at al. C4 nephritic factor (C4NeF) is like C3NeF, this stabilizes the C3-convertase (C4bC2a) commonly used by the lectin and the classical pathway, in a dose-dependent manner.C4NeF was noticed in systemic lupus erythematosus, acute glomerulonephritis, and chronic proliferative glomerulonephritis and was also described in 100 hypocomplementemias MPGN patients with or without C3NeF<ref name="pmid6902727">{{cite journal| author=Halbwachs L, Leveillé M, Lesavre P, Wattel S, Leibowitch J| title=Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. | journal=J Clin Invest | year= 1980 | volume= 65 | issue= 6 | pages= 1249-56 | pmid=6902727 | doi=10.1172/jci109787 | pmc=371461 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6902727  }} </ref><ref name="pmid8306508">{{cite journal| author=Ohi H, Yasugi T| title=Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). | journal=Clin Exp Immunol | year= 1994 | volume= 95 | issue= 2 | pages= 316-21 | pmid=8306508 | doi=10.1111/j.1365-2249.1994.tb06530.x | pmc=1534915 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8306508  }} </ref><ref name="pmid2736802">{{cite journal| author=Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M| title=C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. | journal=Clin Exp Immunol | year= 1989 | volume= 76 | issue= 1 | pages= 82-5 | pmid=2736802 | doi= | pmc=1541731 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2736802  }} </ref><ref name="pmid6903579">{{cite journal| author=Daha MR, van Es LA| title=Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. | journal=J Immunol | year= 1980 | volume= 125 | issue= 5 | pages= 2051-4 | pmid=6903579 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6903579  }} </ref>.
  
 
==References==
 
==References==

Revision as of 19:03, 2 August 2020

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy historical perspective

CDC on C4 glomerulopathy historical perspective

C4 glomerulopathy historical perspective in the news

Blogs on C4 glomerulopathy historical perspective

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

Historical Perspective

C4 Nephritic factor (NeF) was first defined in 1980 by Halbwachs at al. C4 nephritic factor (C4NeF) is like C3NeF, this stabilizes the C3-convertase (C4bC2a) commonly used by the lectin and the classical pathway, in a dose-dependent manner.C4NeF was noticed in systemic lupus erythematosus, acute glomerulonephritis, and chronic proliferative glomerulonephritis and was also described in 100 hypocomplementemias MPGN patients with or without C3NeF[1][2][3][4].

References

  1. Halbwachs L, Leveillé M, Lesavre P, Wattel S, Leibowitch J (1980). "Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme". J Clin Invest. 65 (6): 1249–56. doi:10.1172/jci109787. PMC 371461. PMID 6902727.
  2. Ohi H, Yasugi T (1994). "Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN)". Clin Exp Immunol. 95 (2): 316–21. doi:10.1111/j.1365-2249.1994.tb06530.x. PMC 1534915. PMID 8306508.
  3. Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M (1989). "C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis". Clin Exp Immunol. 76 (1): 82–5. PMC 1541731. PMID 2736802.
  4. Daha MR, van Es LA (1980). "Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein". J Immunol. 125 (5): 2051–4. PMID 6903579.